Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046241 · ClinicalTrials.gov registry record · Phase 3
Prevention of Seasonal Affective Disorder
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00046241 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 300 participants.
The verdict
NCT00046241, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).
Interventions
- DRUG Extended-release bupropion hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046241
The ClinicalTrials.gov registry entry for NCT00046241 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extended-release bupropion hydrochloride is the first listed.
NCT00046241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046241 about?
NCT00046241 is a clinical study titled "Prevention of Seasonal Affective Disorder". This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).
What is the current status of trial NCT00046241?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2002-09. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00046241?
The interventions under investigation include: Extended-release bupropion hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00046241?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.